(MYGN) Myriad Genetics - Ratings and Ratios
Cancer Tests, Genetic Tests, Diagnostic Tests, Health Tests, Prenatal Tests
MYGN EPS (Earnings per Share)
MYGN Revenue
Description: MYGN Myriad Genetics
Myriad Genetics, Inc. (NASDAQ:MYGN) is a molecular diagnostic testing and precision medicine company that develops and provides molecular tests globally, with a focus on oncology, womens health, and pharmacogenomics. The companys product portfolio includes various diagnostic tests such as MyRisk Hereditary Cancer, BRACAnalysis CDx, and MyChoice CDx, which are used to assess cancer risks and determine therapy for various types of cancer.
From a business perspective, Myriad Genetics has established collaborations with prominent institutions such as Illumina, Inc., Memorial Sloan Kettering Cancer Center, and the University of Texas MD Anderson Cancer Center, which can be seen as a validation of their technology and expertise. To further evaluate the companys performance, some key performance indicators (KPIs) to consider are revenue growth, test adoption rates, and the expansion of their test menu. For instance, the companys revenue growth can be assessed by analyzing their quarterly and annual revenue reports.
In terms of financials, Myriad Genetics has a market capitalization of approximately $489.46 million USD, with a forward P/E ratio of 476.19, indicating high growth expectations. However, the companys return on equity (RoE) is negative at -14.09%, suggesting that the company is currently not generating profits. To improve this metric, Myriad Genetics may need to focus on increasing revenue and reducing costs. Some potential KPIs to track include the companys gross margin, operating expenses as a percentage of revenue, and cash flow from operations.
To gain a deeper understanding of Myriad Genetics competitive position, its essential to analyze the companys market share, customer base, and the competitive landscape of the molecular diagnostics industry. The companys ability to innovate and expand its product offerings will be crucial in maintaining its market position and driving future growth. Key metrics to monitor include the companys research and development (R&D) expenses as a percentage of revenue, the number of new test launches, and the companys patent portfolio.
MYGN Stock Overview
| Market Cap in USD | 698m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1995-10-05 |
MYGN Stock Ratings
| Growth Rating | -81.5% |
| Fundamental | 39.7% |
| Dividend Rating | 0.08% |
| Return 12m vs S&P 500 | -78.2% |
| Analyst Rating | 3.33 of 5 |
MYGN Dividends
Currently no dividends paidMYGN Growth Ratios
| Growth Correlation 3m | 71% |
| Growth Correlation 12m | -90.6% |
| Growth Correlation 5y | -55.6% |
| CAGR 5y | -28.67% |
| CAGR/Max DD 3y | -0.33 |
| CAGR/Mean DD 3y | -1.63 |
| Sharpe Ratio 12m | -1.38 |
| Alpha | 0.00 |
| Beta | 0.991 |
| Volatility | 76.32% |
| Current Volume | 1761.6k |
| Average Volume 20d | 1263.3k |
| Stop Loss | 6.9 (-6.8%) |
| Signal | 0.03 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-395.2m TTM) > 0 and > 6% of Revenue (6% = 50.0m TTM) |
| FCFTA -0.06 (>2.0%) and ΔFCFTA 11.31pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.13% (prev 17.79%; Δ -7.66pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.03 (>3.0%) and CFO -22.6m > Net Income -395.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (92.5m) change vs 12m ago 2.10% (target <= -2.0% for YES) |
| Gross Margin 70.44% (prev 69.06%; Δ 1.38pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 94.52% (prev 73.93%; Δ 20.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -108.9 (EBITDA TTM -355.0m / Interest Expense TTM 3.80m) >= 6 (WARN >= 3) |
Altman Z'' -11.52
| (A) 0.12 = (Total Current Assets 284.3m - Total Current Liabilities 199.9m) / Total Assets 677.3m |
| (B) -1.61 = Retained Earnings (Balance) -1.09b / Total Assets 677.3m |
| warn (B) unusual magnitude: -1.61 — check mapping/units |
| (C) -0.47 = EBIT TTM -413.9m / Avg Total Assets 881.2m |
| (D) -3.76 = Book Value of Equity -1.09b / Total Liabilities 289.2m |
| Total Rating: -11.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 39.74
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield -4.92% = -2.46 |
| 3. FCF Margin -4.61% = -1.73 |
| 4. Debt/Equity 0.41 = 2.42 |
| 5. Debt/Ebitda -0.44 = -2.50 |
| 6. ROIC - WACC (= -68.82)% = -12.50 |
| 7. RoE -62.59% = -2.50 |
| 8. Rev. Trend 86.43% = 6.48 |
| 9. EPS Trend 80.49% = 4.02 |
What is the price of MYGN shares?
Over the past week, the price has changed by +7.25%, over one month by +29.60%, over three months by +48.59% and over the past year by -74.13%.
Is Myriad Genetics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MYGN is around 5.68 USD . This means that MYGN is currently overvalued and has a potential downside of -23.24%.
Is MYGN a buy, sell or hold?
- Strong Buy: 3
- Buy: 3
- Hold: 6
- Sell: 2
- Strong Sell: 1
What are the forecasts/targets for the MYGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.4 | -0.3% |
| Analysts Target Price | 7.4 | -0.3% |
| ValueRay Target Price | 6.3 | -14.9% |
Last update: 2025-09-18 04:38
MYGN Fundamental Data Overview
CCE Cash And Equivalents = 74.4m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 53.4759
P/S = 0.8378
P/B = 1.7981
P/EG = 1.4001
Beta = 1.935
Revenue TTM = 832.9m USD
EBIT TTM = -413.9m USD
EBITDA TTM = -355.0m USD
Long Term Debt = 89.3m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 68.4m USD (from shortTermDebt, last quarter)
Debt = 157.7m USD (Calculated: Short Term 68.4m + Long Term 89.3m)
Net Debt = 80.2m USD (from netDebt column, last quarter)
Enterprise Value = 781.1m USD (697.8m + Debt 157.7m - CCE 74.4m)
Interest Coverage Ratio = -108.9 (Ebit TTM -413.9m / Interest Expense TTM 3.80m)
FCF Yield = -4.92% (FCF TTM -38.4m / Enterprise Value 781.1m)
FCF Margin = -4.61% (FCF TTM -38.4m / Revenue TTM 832.9m)
Net Margin = -47.45% (Net Income TTM -395.2m / Revenue TTM 832.9m)
Gross Margin = 70.44% ((Revenue TTM 832.9m - Cost of Revenue TTM 246.2m) / Revenue TTM)
Tobins Q-Ratio = -0.72 (set to none) (Enterprise Value 781.1m / Book Value Of Equity -1.09b)
Interest Expense / Debt = 0.95% (Interest Expense 1.50m / Debt 157.7m)
Taxrate = 21.0% (US default)
NOPAT = -413.9m (EBIT -413.9m, no tax applied on loss)
Current Ratio = 1.42 (Total Current Assets 284.3m / Total Current Liabilities 199.9m)
Debt / Equity = 0.41 (Debt 157.7m / last Quarter total Stockholder Equity 388.1m)
Debt / EBITDA = -0.44 (Net Debt 80.2m / EBITDA -355.0m)
Debt / FCF = -4.11 (Debt 157.7m / FCF TTM -38.4m)
Total Stockholder Equity = 631.5m (last 4 quarters mean)
RoA = -58.35% (Net Income -395.2m, Total Assets 677.3m )
RoE = -62.59% (Net Income TTM -395.2m / Total Stockholder Equity 631.5m)
RoCE = -57.43% (Ebit -413.9m / (Equity 631.5m + L.T.Debt 89.3m))
RoIC = -60.80% (NOPAT -413.9m / Invested Capital 680.8m)
WACC = 8.03% (E(697.8m)/V(855.5m) * Re(9.67%)) + (D(157.7m)/V(855.5m) * Rd(0.95%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 1.25%
Discount Rate = 9.67% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -38.4m)
EPS Correlation: 80.49 | EPS CAGR: 136.0% | SUE: 1.97 | # QB: 1
Revenue Correlation: 86.43 | Revenue CAGR: 11.91% | SUE: 1.78 | # QB: 1
Additional Sources for MYGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle